evipedia.ai
← Back

Gamma-Hydroxybutyrate for Health & Longevity

Created on 11/07/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Gamma-hydroxybutyrate, a natural brain chemical sold as a prescription medication for sleep disorders, is a strong, short-lasting bedtime sedative. In these disorders it reliably deepens night sleep and lessens daytime sleepiness. Use against brain aging or for longer life rests on animal studies and theory. Serious risks: slowed breathing, danger with alcohol or other sedatives, and dependence with frequent unsupervised use. Almost no evidence involves healthy adults using it long-term. (Full Review)

Protocol

Twice-nightly immediate release (narcolepsy)
4.5 g per night in two equal doses
At bedtime and 2.5–4 hours later, increased by 1.5 g weekly to 6–9 g
Deep-sleep research doses (healthy adults)
2.5–3.5 g at bedtime or 50 mg/kg
Single-night laboratory regimens; no longevity practitioner or clinic protocol was identified
Time of day
At bedtime, in bed
At least 2 hours after eating; sleep often begins within 5–15 minutes
Time to effect
Reduced Daytime Sleepiness and Better Alertness
Over weeks of dose increases
13-week trials showed gains at each dose step
Deeper, More Consolidated Night Sleep
First night
In healthy men, the deepened sleep resembled natural recovery sleep
Modest Weight Reduction
13 weeks
BMI lower than placebo in narcolepsy

Benefits

Contraindications
  • SSADH deficiency
  • People who drink alcohol or take sedative hypnotics on dosing nights
  • Compromised respiratory function or moderate-to-severe sleep apnea
  • Pregnancy
  • History of drug abuse: requires close evaluation and monitoring for misuse
  • History of depressive illness or suicide attempt: requires careful monitoring for emergent depression
  • Heart failure, hypertension or kidney impairment (high-sodium formulation)
  • Liver cirrhosis (Child's Class A or C) without dose reduction
  • Occupations needing full alertness within 6 hours of dosing (drivers, pilots)
    •
Key Interactions
  • Other CNS depressants (opioid analgesics, e.g., oxycodone; benzodiazepines, e.g., alprazolam; sedating psychiatric drugs, e.g., mirtazapine; muscle relaxants, e.g., baclofen): respiratory depression, low blood pressure, fainting, death
  • Divalproex sodium (valproate): raises GHB exposure by about 25%; oxybate dose reduced by at least 20%
  • Topiramate: coma with raised plasma GHB levels reported; close monitoring for excess sedation
  • GHB precursors (GBL and 1,4-butanediol): avoid; adds unmeasured GHB and overdose risk
  • High-fat meal: delays absorption and weakens effect
    •
Theoretical (inferred from mechanism)
  • GABA-B activating supplements (phenibut): additive sedation and breathing suppression
  • Sedating herbal supplements (kava, valerian): additive CNS depression
  • Over-the-counter sedating antihistamines (diphenhydramine): additive sedation and impaired arousal from breathing events
  • Sodium-containing supplements and blood-pressure-raising supplements (sodium bicarbonate, licorice root): additive sodium load and blood pressure rise
    •

Risk & Side Effects

  • High: Central nervous system and respiratory depression, overdose and death; nausea, vomiting, dizziness, headache, somnolence and tremor
    •
  • Medium: Sleep-disordered breathing; sleepwalking and bedwetting; confusion, cognitive impairment and psychiatric effects; depression and suicidality
    •
  • Low: Abuse, dependence and withdrawal; higher blood pressure from sodium load; falls and accidents from abrupt sleep onset
    •
  • Speculative: Displacement of REM sleep and natural sleep regulation; fetal harm
    •

Monitoring

Marker Target Why
Blood pressure (home or 24-hour ambulatory) No established target; track change from own baseline Sodium load can raise pressure
Apnea-hypopnea index (sleep study) No established target; track change from baseline, including central apneas New or worse apnea stops or changes use
Epworth Sleepiness Scale (0–24) No established target; track change from own baseline Daytime sleepiness
PHQ-9 depression score (0–27) Below 5, the "minimal" severity band Emerging depression changes use
ALT and AST (liver enzymes) Within the laboratory's reference interval Liver impairment halves starting dose
eGFR Above 60 mL/min/1.73 m² Kidney impairment heightens sodium sensitivity
Body weight and BMI No established target; track change from own baseline Weight often falls

Cadence: Baseline before the first dose; 2 and 4 weeks after starting or after each dose increase, then every 3–6 months once the dose is stable; liver and kidney tests yearly; repeat sleep study whenever snoring, breathing pauses, morning headaches or new sleepiness appear

Qualitative Assessment

  • Morning refreshment and perceived sleep depth
  • Daytime alertness, including unplanned dozing
  • Mood, anxiety and irritability
  • Nausea, dizziness, morning grogginess or confusion
  • Bed partner reports of snoring, breathing pauses, sleepwalking or bedwetting
  • Any urge to raise the dose or take extra doses
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.